人乳头瘤病毒 (HPV) 疫苗市场战略、顶级参与者、增长机会、2028 年分析和预测

  • Report Code : TIPRE00029411
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 277
Buy Now

Human Papillomavirus (HPV) Vaccine Market Forecast to 2028

Buy Now

 

2022 年人乳头瘤病毒 (HPV) 疫苗市场价值为 42.7384 亿美元,预计到 2028 年将达到 57.305 亿美元;预计 2022 年至 2028 年的复合年增长率为 5.0%。

人乳头瘤病毒 (HPV) 是一组多样化的 DNA 病毒,可感染人类和各种动物的粘膜和皮肤膜。目前已鉴定出 100 多种不同类型的 HPV。由 HPV 引起的各种癌症的患病率不断上升,预计将在预测期内推动人乳头瘤病毒 (HPV) 疫苗市场的发展。根据美国疾病控制和预防中心 (CDC) 的数据,HPV 是美国最常见的性传播感染。超过 60% 的阴茎癌、70% 的外阴和阴道癌以及 90% 的肛门癌和宫颈癌都是由 HPV 感染引起的。CDC 还指出,美国每年约有 1400 万人新感染该病毒。

 

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

人乳头瘤病毒 (HPV) 疫苗市场:

人乳头瘤病毒 (HPV) 疫苗市场
  • Human Papillomavirus (HPV) Vaccine Market
    复合年增长率(2022 - 2028)
    5.0%
  • 2022 年市场规模
    42.7 亿美元
  • 2028 年市场规模
    57.3 亿美元

市场动态

增长动力
  • 財政部
  • 財政部
  • 財政部
未来的趋势
  • 財政部
  • 財政部
  • 財政部
机会
  • 財政部
  • 財政部
  • 財政部

关键人物;主力;重要一员

  •  
  • 默克公司
  • 葛兰素史克
  • 印度血清研究所
  • 沃森生物科技
  • 伊诺瓦
  • 真空技术
  • Innovio 制药
  • 成都生物制品研究所有限公司
  • 赛诺菲

区域概况

Human Papillomavirus (HPV) Vaccine Market
  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

Human Papillomavirus (HPV) Vaccine Market类型
  • 9价HPV疫苗
  • 四价 HPV 疫苗
  • 双价 HPV 疫苗
Human Papillomavirus (HPV) Vaccine Market剂量
  • 第 2 剂和第 3 剂
Human Papillomavirus (HPV) Vaccine Market年龄
  • 9 至 14 岁和 15 至 45 岁
Human Papillomavirus (HPV) Vaccine Market应用
  • HPV 致癌物和生殖器疣
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

全球人乳头瘤病毒 (HPV) 疫苗市场根据类型、剂量、年龄、分销渠道和地理位置进行细分。按地区划分,市场分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。该报告提供了对人乳头瘤病毒 (HPV) 疫苗市场的见解和深入分析,重点关注市场趋势、技术进步和市场动态等各种参数。它还包括全球主要市场参与者的竞争格局分析。

 

市场洞察
HPV 相关疾病患病率上升

 

人乳头瘤病毒 (HPV) 是一种常见的性传播感染,可导致宫颈癌、口咽癌以及阴道癌、外阴癌、阴茎癌或肛门癌。它还会导致各种疾病,如肛门生殖器疣和复发性呼吸道乳头状瘤病。在硬化性苔藓、皮赘、脂溢性角化病、表皮囊肿、光化性角化病和银屑病斑块中也检测到了 HPV。HPV 相关疾病的沉重负担可能会推动市场的增长。

在女性中,宫颈癌是第四大常见癌症。根据世界卫生组织 (WHO) 报告估计,2018 年,全球估计有 570,000 名女性患有宫颈癌,约有 311,000 名女性死于宫颈癌。此外,美国临床肿瘤学会 (ASCO) 估计,仅在美国就会登记约 14,100 例浸润性宫颈癌病例。此外,根据《欧盟 27 国宫颈癌负担》报告,2020 年,女性新增病例 30,447 例,因宫颈癌死亡 13,437 例。

此外,根据美国疾病控制和预防中心 (CDC) 的数据,2018 年,美国约有 4300 万人感染 HPV。CDC 还估计,每年约有 19,400 名女性和 12,100 名男性患有由 HPV 引起的癌症。此外,根据美国国家传染病基金会 (NFID) 的数据,美国每年约有 1400 万例新的 HPV 感染病例。此外,根据《欧洲人类乳头瘤病毒和相关疾病报告》,2020 年欧洲有 8,449 名女性和 4,327 名男性患有肛门癌。

全球 HPV 相关感染发病率如此之高,可能有利于未来几年整体市场的增长。

 

基于类型的洞察


根据类型,人乳头瘤病毒 (HPV) 疫苗市场细分为 9 价 HPV 疫苗、四价 HPV 疫苗和二价 HPV 疫苗。2022 年,四价 HPV 疫苗细分市场占有最大市场份额。然而,9 价 HPV 疫苗细分市场的市场预计将在 2022 年至 2028 年期间快速增长。四价人乳头瘤病毒 (HPV) 疫苗可预防 6、11、16 和 18 型 HPV 感染,这些病毒是 70% 至 80% 的宫颈癌和至少 90% 的生殖器疣病例的罪魁祸首。该疫苗可降低生殖器疣的风险以及病毒引起的宫颈癌、阴道癌和外阴癌的前体病变。

 

 

基于剂量的见解

根据剂量,人乳头瘤病毒 (HPV) 疫苗市场分为 2 剂和 3 剂。2022 年,2 剂疫苗将占据更大的市场份额。

基于年龄的洞察

 

 

根据年龄,全球人乳头瘤病毒 (HPV) 疫苗市场分为 9 至 14 岁和 15 至 45 岁。9 至 14 岁年龄段在 2022 年占据了更大的市场份额,预计同一年龄段在预测期内的复合年增长率会更高。

 

基于应用的洞察

 

从应用方面来看,全球人乳头瘤病毒 (HPV) 疫苗市场细分为 HPV 引起的癌症和生殖器疣。HPV 引起的癌症细分市场在 2022 年占据更大的市场份额,预计同一细分市场在预测期内的复合年增长率会更高。

 

基于分销渠道的洞察

根据分销渠道,全球人乳头瘤病毒 (HPV) 疫苗市场分为医生办公室、社区卫生诊所、学校卫生中心、卫生部门、医院等。医院部门在 2022 年占据最大的市场份额,而学校卫生中心部门预计在预测期内将实现最高的复合年增长率。

COVID-19 疫情可能会对 HPV 疫苗业务产生长期影响。美国许多初级保健诊所继续以较低的容量运营,以遵守社交距离措施并采用严格的清洁规程。面对面就诊的减少限制了疫苗供应商讨论和交付疫苗的机会。交通障碍可能会损害 HPV 疫苗接种;制药和生物技术公司传统上很难向大众推销疫苗,因为受到家长的抵制,而且人们对支持其他青少年疫苗的入学要求缺乏广泛认识。现有证据表明,COVID-19 疫情在 2020 年和 2021 年极大地扰乱了 HPV 疫苗的交付。CDC 的早期报告显示,2020 年 3 月的订购和账单下降了 70% 以上。此外,2020 年 6 月,HPV 疫苗订单继续下降 25-50%,而其他儿童早期疫苗订单则回升至接近疫情前的水平。尽管HPV疫苗市场正在复苏,但现有数据显示,短期内HPV疫苗接种覆盖率将大幅下降,长期来看,北美地区对HPV疫苗的需求将会增长。

 

人乳头瘤病毒 (HPV) 疫苗市场报告范围

报告属性细节
2022 年市场规模42.7亿美元
2028 年市场规模57.3亿美元
全球复合年增长率(2022 - 2028)5.0%
历史数据2020-2021
预测期2023-2028
涵盖的领域按类型
  • 9价HPV疫苗
  • 四价 HPV 疫苗
  • 双价 HPV 疫苗
按剂量
  • 第 2 剂和第 3 剂
按年龄
  • 9 至 14 岁和 15 至 45 岁
按应用
  • HPV 致癌物和生殖器疣
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  •  
  • 默克公司
  • 葛兰素史克
  • 印度血清研究所
  • 沃森生物科技
  • 伊诺瓦
  • 真空技术
  • Innovio 制药
  • 成都生物制品研究所有限公司
  • 赛诺菲
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

 

公司通常采用产品发布和扩张战略来扩大其全球业务范围、满足不断增长的需求并扩大其产品组合。在全球人乳头瘤病毒 (HPV) 疫苗市场运营的参与者实施产品创新战略以应对全球客户需求的变化,这也使他们能够在全球范围内保持自己的品牌名称。

  • 2022 年 5 月,中国国家药品监督管理局 (NMPA) 批准葛兰素史克 (GSK) 的两剂疫苗方案 Cervarix,用于 9 至 14 岁的女孩预防宫颈癌。Cervarix 是一种重组、非感染性、AS04 佐剂 HPV 双价(16、18 型)疫苗。
  • 2022 年 5 月,印度血清研究所宣布开发了一种四价 HPV 疫苗,其中包括血清型 6、11、16、18 的 L1 VLP,预计对乳头瘤病毒的覆盖率约为 90%。该疫苗目前正在开发中。
  • 2020年5月,上海博维生物科技与重庆博维生物制药合作,对4价和9价HPV重组疫苗的免疫原性和安全性进行评估。

按地域划分,人乳头瘤病毒 (HPV) 疫苗市场细分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙、俄罗斯、白俄罗斯和欧洲其他地区)、亚太地区(中国、日本、印度、澳大利亚、东南亚、新西兰、韩国和亚太地区其他地区)、中东和非洲(阿联酋、沙特阿拉伯、南非、伊朗、土耳其、科威特、巴林、埃及和中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷、智利、危地马拉、秘鲁、哥伦比亚和南美洲和中美洲其他地区)。葛兰素史克;Innovax;Walvax;Serum Institute of India Pvt., Ltd.;Vaccitech;Innovio Pharmaceuticals;默克公司;2A Pharm;成都生物制品研究所有限公司;赛诺菲;R-Pharm;上海博威;和 BioLeaders 是市场上领先的公司之一。

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Who are the major players in market the human papillomavirus vaccine market?

The human papillomavirus vaccine market majorly consists of the players such Merck & Co. In., GSK, Serum Institute of India, Walvax Biotechnologies, Innovax, Vaccitech, Innovio Pharmaceuticals, Chengdu Institute of Biological Products Co., Ltd., Sanofi, R-Pharm, Shanghai Bowei, and Bioleaders amongst others.

Which segment is dominating the human papillomavirus vaccine market?

The human papillomavirus vaccine market, by type, is bifurcated 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. In 2022, the quadrivalent HPV vaccine segment held the largest share of the market, by type. However, the 9-valent HPV vaccine segment is expected to witness the fastest growth during 2022 to 2028.

What are the driving factors for the human papillomavirus vaccine market across the country?

Driving factor such as increase in prevalence of HPV associated diseases and initiatives taken by global health organizations are likely to have a positive impact on the growth of the global human papillomavirus (HPV) vaccines market. Whereas factors, such as growing number of HPV awareness programs, are likely to create a growth opportunity on the HPV vaccines market in the near future.

What is the human papillomavirus vaccine market?

Human papillomaviruses is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of human papillomavirus have been characterized. Increasing prevalence of various cancers caused by human papillomavirus is expected to drive the market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), human papillomavirus is the most common sexually transmitted infection in the U.S. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to human papillomavirus infection. CDC also states that about 14 million people are newly infected by human papillomavirus every year in the U.S.

The List Of Companies - HPV Vaccines Market

  1. Merck & Co. In.
  2. GSK
  3. Serum Institute of India
  4. Walvax Biotechnologies
  5. Innova
  6. Vaccitech
  7. Innovio Pharmaceuticals
  8. Chengdu Institute of Biological Products Co., Ltd.
  9. Sanofi
  10. R-Pharm
  11. Shanghai Bowei
  12. Bioleaders

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..